ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Generic Drug

Also written as “Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043” and “Generic 0.5% 5-fluorouracil cream”.

Its studies are mostly in Triple Negative Breast Neoplasms · Keratosis, Actinic, led by 2 companies.

Drug pageGeneric Drug: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 28, 20262 company-led studies, 1 open or runningNext primary completion: Nov 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group11 open or runningphase 3since Sep 28, 2026Sep 28, 2026Nov 30, 2028phase 3 · NCT07879911
Spear Pharmaceuticalsits history only10 open or runningphase 3since May 14, 2011May 14, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2026First study: phase 3 study in Triple Negative Breast NeoplasmsFirst studyNCT07879911 · 550 planned

Ahead

  1. Nov 30, 2028Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT07879911

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study CSPC Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07879911Triple Negative Breast Neoplasms3Not yet recruitingNov 30, 2028550

How it is read

Names in the registry

  • “Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043”, 1 entry
  • “Generic 0.5% 5-fluorouracil cream”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.